Pfizer Inc.has decided not to move forward with the development of an oral PCSK9 inhibitor for the treatment of high cholesterol, President-Worldwide R&D Mikael Dolsten revealed during the company’s second quarter sales and earnings call Aug. 2.
“We don’t think the profile will be competitive,” Dolsten said, pointing to the strong efficacy seen in Phase III clinical...